Description: Medivir AB (publ) researches, develops, and sells pharmaceuticals primarily for the treatment of oncology in Sweden and internationally. The company markets Xerclear for the treatment of labial herpes under the Zoviduo name. It also develops Remetinostat for treating MF cutaneous T-cell lymphoma, as well as basal cell carcinoma. In addition, the company develops MIV-818 for the treatment of liver cancer; MIV-711 to treat osteoarthritis; and Birinapant and IGM-8444 for the treatment of solid tumors. It has a research collaboration with the Drug Discovery and Development Platform at SciLifeLab for the discovery of antivirals for SARS CoV-2; and a licensing agreement with the Tango Therapeutics for a preclinical research program, as well as Ubiquigent Limited for the preclinical research program USP7. Medivir AB (publ) was incorporated in 1987 and is based in Huddinge, Sweden.
Home Page: www.medivir.com
Lunastigen 5
Huddinge,
Sweden
Phone:
46 8 54 68 31 00
Officers
| Name | Title |
|---|---|
| Mr. Magnus Christensen | Chief Financial Officer |
| Mr. Jens Lindberg | Chief Exec. Officer |
| Mr. Fredrik Öberg | Chief Scientific Officer & Chief Medical Officer |
| Dr. Thomas Morris | Interim Chief Medical Officer |
| Karin Tunblad | Sr. Principal Scientist & MIV-818 Project Leader |
Exchange: ST
Country: SE
Currency: Swedish krone (kr)
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 2.5392 |
| Price-to-Sales TTM: | 32.5252 |
| IPO Date: | |
| Fiscal Year End: | December |
| Full Time Employees: | 9 |